Minerva Neurosciences (NERV) Amortization of Deferred Charges (2021)
Minerva Neurosciences (NERV) posted Amortization of Deferred Charges of $14939.0 for Q3 2021, down 66.06% on a QoQ basis from $44014.0 in Q2 2021.
Minerva Neurosciences (NERV) Amortization of Deferred Charges (2021) Analysis & Trends
Minerva Neurosciences' Amortization of Deferred Charges history runs 1 years deep, the most recent figure standing at $14939.0 for Q3 2021.
- Quarterly Amortization of Deferred Charges changed N/A year-over-year to $14939.0 in Q3 2021, while the trailing twelve-month figure through Dec 2021 was $101786.0 (changed N/A YoY) and the FY2021 annual result came in at $101786.0, down 36.45% from the prior year.
- Amortization of Deferred Charges was $14939.0 for Q3 2021 at Minerva Neurosciences, down from $44014.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $44014.0 in Q2 2021 and bottomed at $14939.0 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - |
| 4 | BeOne Medicines | 470.64 Bn | 465.84 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.91 Bn | 115.67 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.77 Bn | 62.77 Bn | - |
| 8 | Argenx Se | 56.21 Bn | 51.02 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.60 Bn | 37.60 Bn | - |
| 10 | Minerva Neurosciences | 181.97 Mn | 181.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 14,939.00 |
| Sep 30, 2021 | 14,939.00 |
| Jun 30, 2021 | 44,014.00 |
| Jun 30, 2021 | 44,014.00 |
| Mar 31, 2021 | 42,833.00 |
| Mar 31, 2021 | 42,833.00 |